AU2010277505B2 - APAF-1 inhibitor compounds - Google Patents

APAF-1 inhibitor compounds Download PDF

Info

Publication number
AU2010277505B2
AU2010277505B2 AU2010277505A AU2010277505A AU2010277505B2 AU 2010277505 B2 AU2010277505 B2 AU 2010277505B2 AU 2010277505 A AU2010277505 A AU 2010277505A AU 2010277505 A AU2010277505 A AU 2010277505A AU 2010277505 B2 AU2010277505 B2 AU 2010277505B2
Authority
AU
Australia
Prior art keywords
ethyl
dioxo
dichlorophenethyl
thiophen
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010277505A
Other languages
English (en)
Other versions
AU2010277505A1 (en
Inventor
Juanlo Catena Ruiz
Natividad Garcia Villar
Daniel Gonzalez Pinacho
Isabel Masip Masip
Angel Messeguer Peypoch
Ester Monlleo Mas
Alejandra Moure Fernandez
Enrique Perez Paya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spiral Therapeutics Inc
Original Assignee
Spiral Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spiral Therapeutics Inc filed Critical Spiral Therapeutics Inc
Publication of AU2010277505A1 publication Critical patent/AU2010277505A1/en
Application granted granted Critical
Publication of AU2010277505B2 publication Critical patent/AU2010277505B2/en
Assigned to LOOP THERAPEUTICS INC. reassignment LOOP THERAPEUTICS INC. Request for Assignment Assignors: LABORATORIOS SALVAT, S.A.
Assigned to SPIRAL THERAPEUTICS INC reassignment SPIRAL THERAPEUTICS INC Request for Assignment Assignors: LOOP THERAPEUTICS INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
AU2010277505A 2009-07-30 2010-07-29 APAF-1 inhibitor compounds Ceased AU2010277505B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200901757 2009-07-30
ESP200901757 2009-07-30
PCT/ES2010/000349 WO2011012746A2 (es) 2009-07-30 2010-07-29 Compuestos inhibidores de apaf-1

Publications (2)

Publication Number Publication Date
AU2010277505A1 AU2010277505A1 (en) 2012-03-08
AU2010277505B2 true AU2010277505B2 (en) 2016-01-14

Family

ID=43529761

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010277505A Ceased AU2010277505B2 (en) 2009-07-30 2010-07-29 APAF-1 inhibitor compounds

Country Status (15)

Country Link
US (1) US9040701B2 (cg-RX-API-DMAC10.html)
EP (1) EP2460798B1 (cg-RX-API-DMAC10.html)
JP (1) JP5694320B2 (cg-RX-API-DMAC10.html)
KR (1) KR101786761B1 (cg-RX-API-DMAC10.html)
CN (1) CN102574818B (cg-RX-API-DMAC10.html)
AU (1) AU2010277505B2 (cg-RX-API-DMAC10.html)
BR (1) BR112012002134B8 (cg-RX-API-DMAC10.html)
CA (1) CA2769408C (cg-RX-API-DMAC10.html)
EA (1) EA021838B1 (cg-RX-API-DMAC10.html)
ES (1) ES2727711T3 (cg-RX-API-DMAC10.html)
IN (1) IN2012DN01378A (cg-RX-API-DMAC10.html)
MX (1) MX2012001339A (cg-RX-API-DMAC10.html)
NZ (1) NZ598125A (cg-RX-API-DMAC10.html)
TR (1) TR201907804T4 (cg-RX-API-DMAC10.html)
WO (1) WO2011012746A2 (cg-RX-API-DMAC10.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138380A2 (en) 2005-06-15 2006-12-28 Massachusetts Institute Of Technology Amine-containing lipids and uses thereof
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US9193827B2 (en) 2010-08-26 2015-11-24 Massachusetts Institute Of Technology Poly(beta-amino alcohols), their preparation, and uses thereof
CA2831392C (en) 2011-03-28 2020-04-28 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
WO2013078413A1 (en) * 2011-11-22 2013-05-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Modulators of lipid storage
EP3536787A1 (en) 2012-06-08 2019-09-11 Translate Bio, Inc. Nuclease resistant polynucleotides and uses thereof
ES2443538B1 (es) * 2012-07-19 2014-11-26 Consejo Superior De Investigaciones Cientificas (Csic) Compuestos beta-lactámicos inhibidores de APAF1
WO2014028487A1 (en) 2012-08-13 2014-02-20 Massachusetts Institute Of Technology Amine-containing lipidoids and uses thereof
KR102311614B1 (ko) 2013-03-14 2021-10-08 샤이어 휴먼 지네틱 테라피즈 인크. Cftr mrna 조성물 및 관련 방법 및 사용
EA201591229A1 (ru) 2013-03-14 2016-01-29 Шир Хьюман Дженетик Терапис, Инк. Способы очистки матричной рнк
US9315472B2 (en) 2013-05-01 2016-04-19 Massachusetts Institute Of Technology 1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
ES2707966T3 (es) 2013-10-22 2019-04-08 Translate Bio Inc Terapia de ARNm para la deficiencia en síntesis de argininosuccinato
EP3574923A1 (en) 2013-10-22 2019-12-04 Translate Bio, Inc. Mrna therapy for phenylketonuria
EP4729528A3 (en) 2014-04-25 2026-06-24 Translate Bio, Inc. Methods for purification of messenger rna
WO2015184256A2 (en) 2014-05-30 2015-12-03 Shire Human Genetic Therapies, Inc. Biodegradable lipids for delivery of nucleic acids
KR102559979B1 (ko) 2014-06-24 2023-07-25 샤이어 휴먼 지네틱 테라피즈 인크. 핵산의 전달용 입체화학적으로 풍부한 조성물
WO2016004202A1 (en) 2014-07-02 2016-01-07 Massachusetts Institute Of Technology Polyamine-fatty acid derived lipidoids and uses thereof
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
MX2019010155A (es) 2017-02-27 2020-12-10 Translate Bio Inc Arnm de cftr optimizado por codón novedoso.
IL270631B2 (en) 2017-05-16 2024-03-01 Translate Bio Inc Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
AU2019256527B2 (en) 2018-04-19 2025-01-23 Spiral Therapeutics, Inc. Inner ear drug delivery devices and methods of use
US11174500B2 (en) 2018-08-24 2021-11-16 Translate Bio, Inc. Methods for purification of messenger RNA
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
EP3930805A1 (en) 2019-02-25 2022-01-05 Spiral Therapeutics, Inc. Intratympanic injector devices and needles for delivery of drugs and methods of use
CA3155003A1 (en) 2019-09-20 2021-03-25 Translate Bio, Inc. Mrna encoding engineered cftr
CN115426991A (zh) 2020-01-24 2022-12-02 斯皮拉尔诊疗有限公司 用于治疗耳部疾病的装置、系统和方法
CN118103042A (zh) * 2021-08-17 2024-05-28 国家科学研究中心 新型血清素衍生物及其用于治疗铁相关病症的用途
EP4137131A1 (en) * 2021-08-17 2023-02-22 Centre National de la Recherche Scientifique (CNRS) Novel serotonin analogues and their uses for treating iron-associated disorders
CN115124449B (zh) * 2022-05-24 2024-02-02 上海英诺富成生物科技有限公司 一种吲哚化合物及制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281585A (en) * 1991-05-07 1994-01-25 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3560503A (en) * 1968-09-18 1971-02-02 Council Scient Ind Res Di-lower alkyl-substituted octahydropyrazinopyrimidinones
GB1284582A (en) * 1969-11-10 1972-08-09 Council Scient Ind Res Substituted piperazinopyrimidinones
JPH04234375A (ja) * 1990-12-27 1992-08-24 Ajinomoto Co Inc 新規2,5−ジオキソピペラジン化合物及びその製造法
JPH05117246A (ja) * 1991-10-23 1993-05-14 Ajinomoto Co Inc 新規2,5−ジオキソピペラジン化合物とその製造法及びα−L−アスパルチル−L−フエニルアラニンメチルエステル誘導体の製造法
AU2871195A (en) * 1994-06-23 1996-01-19 Affymax Technologies N.V. Methods for the synthesis of diketopiperazines
DE60201415T2 (de) * 2001-01-19 2006-02-09 Pharmacopeia, Inc. Bisarylderivate mit fsh rezeptor modulierender aktivität
DK1571970T3 (da) * 2002-10-02 2011-11-28 Dmi Biosciences Inc Diagnose og monitorering af sygdomme
WO2005052177A1 (ja) * 2003-11-28 2005-06-09 Kyowa Hakko Kogyo Co., Ltd. ジペプチドの製造法
ES2296484B1 (es) * 2005-11-23 2009-04-01 Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) Composicion farmaceutica para inhibir la apoptosis.
ES2293834B1 (es) * 2006-07-20 2009-02-16 Consejo Superior Investig. Cientificas Compuesto con actividad inhibidora de las interacciones ubc13-uev, composiciones farmaceuticas que lo comprenden y sus aplicaciones terapeuticas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281585A (en) * 1991-05-07 1994-01-25 Merck & Co., Inc. Fibrinogen receptor antagonists for inhibiting aggregation of blood platelets

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Goktalay, G., et al, European Journal of Pharmacology, 2006, 530, 95-102 *
Saxena, R., et al, Journal of Medicinal Chemistry, 1971, 14(10), 929-31 *

Also Published As

Publication number Publication date
KR101786761B1 (ko) 2017-10-18
CA2769408C (en) 2017-09-05
JP2013500314A (ja) 2013-01-07
CN102574818A (zh) 2012-07-11
BR112012002134B8 (pt) 2021-05-25
NZ598125A (en) 2014-05-30
TR201907804T4 (tr) 2019-06-21
EP2460798B1 (en) 2019-02-27
ES2727711T3 (es) 2019-10-18
US9040701B2 (en) 2015-05-26
KR20120052354A (ko) 2012-05-23
AU2010277505A1 (en) 2012-03-08
IN2012DN01378A (cg-RX-API-DMAC10.html) 2015-06-05
CN102574818B (zh) 2015-02-25
CA2769408A1 (en) 2011-02-03
WO2011012746A3 (es) 2011-07-14
EP2460798A2 (en) 2012-06-06
EA201270215A1 (ru) 2012-11-30
MX2012001339A (es) 2012-03-07
WO2011012746A2 (es) 2011-02-03
US20120122868A1 (en) 2012-05-17
BR112012002134B1 (pt) 2021-03-02
BR112012002134A2 (pt) 2016-05-31
EA021838B1 (ru) 2015-09-30
EP2460798A4 (en) 2013-02-27
JP5694320B2 (ja) 2015-04-01

Similar Documents

Publication Publication Date Title
AU2010277505A1 (en) APAF-1 inhibitor compounds
KR102759005B1 (ko) Pad4의 헤테로아릴 억제제
CZ300131B6 (cs) Zpusob prípravy meziproduktu inhibujících proteázy retroviru
HUP0303484A2 (hu) Melanokortin receptor modulátoraiként hasznos vegyületek és a vegyületeket tartalmazó gyógyszerkészítmények
MX2014005638A (es) Moduladores del receptor mas acoplado a la proteina g y el tratamiento de trastornos relacionados con el mismo.
EA004805B1 (ru) 5-аминоиндено [1, 2-c]пиразол-4-оны в качестве противораковых и антипролиферативных агентов
CA2765150A1 (en) 2, 3-dihydro-1h-indene compounds and their use to treat cancer
CA2887497A1 (en) Dimeric compounds
CN100374115C (zh) 作为催产素拮抗剂的取代的二酮哌嗪类
JP2010536893A (ja) 1,3−ジヒドロイソインドール誘導体
Paul et al. Triazolopeptides: chirospecific synthesis and cis/trans prolyl ratios of structural isomers
KR20060009933A (ko) 시아노플루오로피롤리딘 유도체
CN110143925A (zh) 乙内酰脲异羟肟酸类组蛋白去乙酰化酶6亚型选择性抑制剂及制备方法和应用
AU2012229859A1 (en) Nitrogen-containing saturated heterocyclic compound
RS60952B1 (sr) Postupak za dobijanje derivata azotnih iperita
JP5841059B2 (ja) キナゾリン誘導体
TW200946515A (en) 4-methyl-4,5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist
CN103396405A (zh) 具有parp抑制作用的苯并咪唑-4-甲酰胺衍生物
CN110759892B (zh) Meridianin类衍生物及其制备和在防治植物病毒病菌病中的应用
CN101014588A (zh) 吡咯衍生物,它们的制备和它们的治疗用途
NZ587824A (en) Novel method for the production of sulphonylpyrroles as hdac inhibitors
ES2439322T3 (es) Derivados de amino alcohol y sus actividades terapéuticas
Aly Synthesis of some functionalized 3-(4-thioxo-3, 4-dihydroquinazolin-2-yl) acrylic acid of pharmaceutical interest
CN113480524B (zh) 生物碱hamacanthins系列衍生物及其制备方法和用途
EA014874B1 (ru) Соединения для ингибирования апоптоза

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: LOOP THERAPEUTICS INC.

Free format text: FORMER OWNER WAS: LABORATORIOS SALVAT, S.A.

PC Assignment registered

Owner name: SPIRAL THERAPEUTICS INC

Free format text: FORMER OWNER(S): LOOP THERAPEUTICS INC.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired